Core Viewpoint - Dechra Pharmaceuticals-B (06996) announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental new drug application (sNDA) for Selinexor (Karyopharm Therapeutics) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systemic therapy and are not eligible for autologous stem cell transplantation [1] Group 1 - The approval is specifically for adult patients with relapsed or refractory DLBCL [1] - The treatment is intended for patients who have undergone at least two lines of systemic therapy [1] - The approval indicates a significant step in expanding treatment options for a specific patient population [1]
德琪医药-B：希维奥 在马来西亚获批用于治疗弥漫大B细胞淋巴瘤一种新适应症